adminの記事一覧

Effect of pitavastatin on urinary liver-type fatty-acid-binding protein in patients with nondiabetic mild chronic kidney disease.

Am J Nephrol. 26(1): 82-86, 2006.PubMed

Liver-type fatty acid-binding protein attenuates renal injury induced by unilateral ureteral obstruction.

Am J Pathol. 169(4): 1107-1117, 2006.PubMed

Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney disease.

Mol Cell Biochem. 284(1-2): 175-182, 2006.PubMed

Quantification of L-type fatty acid binding protein in the urine of preterm neonates.

Early Hum Dev. 81(7): 643-646, 2005.PubMed

特定健診の実施率の高い都道府県は透析導入率が低い　慢性腎臓病(CKD)が減少

■━━━━━━━━━━━━━━━━━━━━━━━━■腎疾患診断用バイオマーカー L-FABP情報サイト■□■□メールマガジン□■□■No.63／2023年11月配信号［医療者向け］https://fabp.jp/?utm_source=mailmagazine&utm_campaign=23

Clinical Significance of Urinary Liver-Type Fatty acid-binding Protein in Patients With Diabetic Nephropathy.

Diabetes Care. 28(18): 2038-2039, 2005.PubMed

Candesartan reduces urinary fatty acid-binding protein excretion in patients with autosomal dominant polycystic kidney disease.

TAm J Med Sci. 330(4): 161-165, 2005.PubMed

Effect of Pitavastatin on Urinary Liver-Type Fatty acid-binding Protein Levels in Patients With Early Diabetic Nephropathy.

Diabetes Care. 28(11): 2728-2732, 2005.PubMed

Urinary liver-type fatty acid-binding protein: discrimination between IgA nephropathy and thin basement membrane nephropathy.

Am J Nephrol. 25(5): 447-450, 2005.PubMed

Clinical evaluation of urinary excretion of liver-type fatty acid-binding protein as a marker for the monitoring of chronic kidney disease: A multicenter trial.

J Lab Clin Med. 145(3): 125-133, 2005.PubMed